Non-canonical activation of receptor tyrosine kinases in cancer progression

Hiroaki Sakurai*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Receptor tyrosine kinases (RTKs) are known to be key regulators of cancer cell proliferation, migration, invasion and metastatic spread. Ligand-binding to the extracellular domain triggers canonical activation of the intracellular tyrosine kinase domain. In contrast, it has become evident that RTKs are also regulated by non-canonical tyrosine kinaseindependent mechanisms via phosphorylation of their serine/threonine residues. In this review, I mainly introduce our recent findings on the non-canonical regulation of epidermal growth factor receptor (EGFR), ErbB2 and erythropoietin-producing hepatocellular receptor A2 (EphA2), and discuss the roles of non-canonical activation of RTKs in cancer progression and resistance to targeted cancer agents. Further characterization of non-canonical regulation will contribute to the development of new target cancer therapies.

Original languageEnglish
Pages (from-to)141-144
Number of pages4
JournalYakugaku Zasshi
Volume137
Issue number2
DOIs
StatePublished - 2017

Keywords

  • Cancer
  • Cytokine
  • Epidermal growth factor receptor
  • Erythropoietin-producing hepatocellular receptor A2
  • Growth factor
  • Receptor tyrosine kinase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Non-canonical activation of receptor tyrosine kinases in cancer progression'. Together they form a unique fingerprint.

Cite this